|Notification date||01 October 2010|
|Topic Selection:||16 December 2010|
- If you have any queries please email firstname.lastname@example.org
If you would like to become a registered stakeholder in the development of guidance on this technology, please complete a stakeholder registration and confidentiality form (Word), and return to us at email@example.com.
Registered stakeholders will be informed of key stages in the development of guidance including when documents go out to consultation or comment.
|26 May 2016||Discontinued. NICE was unable to develop medical technologies guidance on the OraQuick® HCV Rapid Antibody Test. Please contact firstname.lastname@example.org for more information. NICE has since developed a Medtech Innovation Briefing (MIB24) on the technology.|
|5 August 2011||NICE's assessment of this medical technology is suspended.|
|29 June 2011||NICE is unable to develop medical technology guidance on OraQuick HCV Rapid Antibody Test because the manufacturer has decided not to pursue a submission for evaluation to the Medical Technologies Evaluation Programme (MTEP). NICE will therefore not be developing guidance on this topic.|
For further information on how we develop guidance, please see our page about NICE medical technologies guidance